ATYR Company Profile and Key Details

NASDAQ : ATYR

aTyr Pharma

$0.56

-0.0018-0.32%

At Close 4:00 PM

$0.54

−0.0216-3.86%

After-Market 07:30 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

aTyr Pharma, Inc. (ATYR) stock declined over -0.32%, trading at $0.56 on NASDAQ, down from the previous close of $0.56. The stock opened at $0.56, fluctuating between $0.54 and $0.59 in the recent session.

Stock Snapshot

0.5615

Prev. Close

54.88M

Market Cap

0.5426

Day Low

-0.77

P/E Ratio

-0.73

EPS (TTM)

N/A

Cash Flow per Share

0.56

Open

98.05M

Number of Shares

0.59

Day High

97.94%

Free Float in %

N/A

Book Value

1.79M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 25, 2026	0.58	0.59	0.54	0.56	1.79M
Jun 24, 2026	0.52	0.59	0.51	0.56	3.63M
Jun 23, 2026	0.46	0.56	0.46	0.54	2.88M
Jun 22, 2026	0.45	0.49	0.45	0.47	1.88M
Jun 18, 2026	0.48	0.49	0.45	0.45	1.53M
Jun 17, 2026	0.44	0.50	0.44	0.46	1.58M
Jun 16, 2026	0.44	0.46	0.44	0.45	643.16K
Jun 15, 2026	0.47	0.48	0.44	0.44	1.61M
Jun 12, 2026	0.47	0.48	0.44	0.44	1.42M
Jun 11, 2026	0.47	0.48	0.44	0.48	1.22M
Jun 10, 2026	0.46	0.48	0.45	0.47	967.16K
Jun 09, 2026	0.46	0.47	0.44	0.46	1.78M
Jun 08, 2026	0.47	0.47	0.44	0.44	1.77M
Jun 05, 2026	0.52	0.52	0.46	0.47	2.78M
Jun 04, 2026	0.51	0.54	0.51	0.51	1.47M
Jun 03, 2026	0.51	0.53	0.50	0.50	1.71M
Jun 01, 2026	0.53	0.59	0.51	0.55	4.42M
May 29, 2026	0.54	0.57	0.52	0.54	5.41M
May 28, 2026	0.48	0.50	0.46	0.49	9.55M
May 27, 2026	0.50	0.50	0.47	0.48	2.51M

Contact Details

San Diego, CA 92121

United States

https://www.atyrpharma.com 858 731 8389

About Company

aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.

Stock Peers

ARGX

36.15+4.24%

argenx SE$888.65 REGN

-3.29-0.53%

Regeneron Pharmaceuticals, Inc.$620.14 UTHR

-6.51-1.18%

United Therapeutics Corporation$543.39 MDGL

4.03+0.79%

Madrigal Pharmaceuticals, Inc.$513.79 VRTX

4.98+1.05%

Vertex Pharmaceuticals Incorporated$480.18 KRYS

12.3+3.54%

Krystal Biotech, Inc.$359.93 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

18.92+6.12%

Praxis Precision Medicines, Inc.$327.86 LGND

11.01+3.86%

Ligand Pharmaceuticals Incorporated$295.92 ALNY

-0.89-0.30%

Alnylam Pharmaceuticals, Inc.$293.17

Company Overview

The stock is currently mid-range between its 52-week high and low $0.40 and $7.29. With a market capitalization of about $54.88 million, aTyr Pharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.54). Key stats such as the average daily volume over the past year has been around 2.38 million shares, in line with its 52-week average. Headquartered in San Diego, CA, aTyr Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sanjay S. Shukla, the company employs approximately 56 people and listed since May 07, 2015. aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions.

Technical Performance

ATYR has shown mixed momentum, gaining 3.44% over the past week and -30.74% over the past quarter, though year-to-date performance is down -9.78%. Short-term trend indicators are mixed aligned (SMA20 5.2%, SMA50 22.05%, SMA200 -62.64%). The stock’s 14-day RSI is 59.04 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -86.42% below its high and over 54.69% above its low. Average 10-day trading volume of 1.94 million shares is below the 3-month average of 2.43 million, indicating normal recent market interest.

Valuation Metrics

aTyr Pharma, Inc. trades at a P/E ratio of -0.75, slightly below the S&P 500 average, with a price-to-sales ratio of 283.01 and a price-to-book ratio of 0.93 suggesting the stock is closer to book value. The P/FCF stands at -0.91, also above market averages.

Dividend & Fair Value

aTyr Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.02. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

aTyr Pharma, Inc. generated EPS of -$0.83 over the past year. Five-year average earnings growth is 34.28%. Wall Street analysts project EPS growth of 16.68% annually over the next five years. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $17.00 to $1.00. The high target offers 2935.71% upside. The low target suggests 78.57% downside. The mean target is $4.80. This offers 757.14% upside. aTyr Pharma, Inc. earnings surprise history is a mixed track record. The quarter that ended May 15, 2026, missed forecasts by -31.25%. The prior quarter beat by -22.22%. Over the last six quarters, Apple has recorded several small beats. These include -21.74% in March 13, 2025.

Shareholding & Insider Activity

aTyr Pharma, Inc. has 98.05 million shares outstanding. The public float is 95.51 million shares, elevated short interest at 23.72% of float. This equals 20.19 million shares. The short ratio is 4.77 days. Institutional investors hold 64.35% of the float. Insiders own 1.43%. EcoR1 Capital Fund Qualified, L.P. holds 3.21 million shares, SCHIMMEL PAUL has 779.14 thousand shares and Shukla Sanjay has 153.55 thousand shares. Over the past six months, insider transactions show net selling. They sold 6.42 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, aTyr Pharma has not generated any revenue.
On valuation metrics, aTyr Pharma trades at a P/E of -0.75, P/S of 283.01 and P/B of 0.93. The current ratio is 5.78 and quick ratio is 5.78. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 871.70 days. Debt-to-equity is 0.20, supported by a cash flow-to-debt ratio of -5.05.

Price Forecast & Outlook

Our AI price prediction model suggests that aTyr Pharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -21.39%, with price expected at $0.44 by July 08, 2026, within a range of $0.29 to $0.60 3-Month Outlook: Projected fall of -78.56%, reaching $0.12 by September 22, 2026, with a range of $0.00 to $0.23. 1-Year Outlook: Projected gain of 87.6%, with price at $1.05 by June 24, 2027, within a range of $0.00 to $0.00.

Key Takeaways

aTyr Pharma, Inc. (NASDAQ:ATYR) shares are flat -9.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows aTyr Pharma, Inc. trading at a premium to the broader market with a P/E of -0.75. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.50, suggesting 3384.01% upside. Our AI forecast model points to short-term weakness (-21.39% over two weeks), a medium-term fall (-78.56% over three months), and a longer-term gain (87.6% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current aTyr Pharma, Inc. (ATYR) stock price?

aTyr Pharma, Inc. (NASDAQ: ATYR) stock price is $0.56 in the last trading session. During the trading session, ATYR stock reached the peak price of $0.59 while $0.54 was the lowest point it dropped to. The percentage change in ATYR stock occurred in the recent session was -0.32% while the dollar amount for the price change in ATYR stock was - $0.00.

ATYR's industry and sector of operation?

The NASDAQ listed ATYR is part of Biotechnology industry that operates in the broader Healthcare sector. aTyr Pharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ATYR?

No Data

How ATYR did perform over past 52-week?

ATYR's closing price is 41.7% higher than its 52-week low of $0.40 where as its distance from 52-week high of $7.29 is -92.32%.

How many employees does ATYR have?

Number of ATYR employees currently stands at 56.

Link for ATYR official website?

Official Website of ATYR is: https://www.atyrpharma.com

How do I contact ATYR?

ATYR could be contacted at phone 858 731 8389 and can also be accessed through its website. ATYR operates from 10240 Sorrento Valley Road, San Diego, CA 92121, United States.

How many shares of ATYR are traded daily?

ATYR stock volume for the day was 1.79M shares. The average number of ATYR shares traded daily for last 3 months was 2.38M.

What is the market cap of ATYR currently?

The market value of ATYR currently stands at $54.88M with its latest stock price at $0.56 and 98.05M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	56
Beta	0.54
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

ATYR Company Profile and Key Details

aTyr Pharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Financial & Profitability Overview

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways